 NEW YORK, April 25, 2022 GLOBE NEWSWIRE -- Cognition Therapeutics , Inc. NASDAQ: CGTX, a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster at the annual meeting of The Association for Research in Vision and Ophthalmology ARVO summarizing preclinical results showing that sigma-2 σ-2 receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration dry AMD. Cognition plans to initiate a Phase 2 clinical study for CT1812, the companys lead σ-2 receptor modulator, in patients with dry AMD. 